Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Eur Acad Dermatol Venereol ; 31(10): 1581-1594, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28786499

RESUMEN

The term 'sclerosing diseases of the skin' comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this guideline provides clinicians with an overview of the diagnosis and treatment of scleromyxedema, scleredema (of Buschke) and nephrogenic systemic sclerosis (nephrogenic fibrosing dermopathy).


Asunto(s)
Dermopatía Fibrosante Nefrogénica/diagnóstico , Dermopatía Fibrosante Nefrogénica/terapia , Escleredema del Adulto/diagnóstico , Escleredema del Adulto/terapia , Escleromixedema/diagnóstico , Escleromixedema/terapia , Diagnóstico Diferencial , Humanos , Dermopatía Fibrosante Nefrogénica/patología , Escleredema del Adulto/patología , Escleromixedema/patología
2.
J Eur Acad Dermatol Venereol ; 31(9): 1401-1424, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28792092

RESUMEN

The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this guideline provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes of systemic sclerosis with diseases of the rheumatological spectrum.


Asunto(s)
Esclerodermia Localizada , Esclerodermia Sistémica , Enfermedades Indiferenciadas del Tejido Conectivo , Humanos , Diagnóstico Diferencial , Europa (Continente) , Examen Físico , Pronóstico , Esclerodermia Localizada/diagnóstico , Esclerodermia Localizada/patología , Esclerodermia Localizada/terapia , Esclerodermia Sistémica/diagnóstico , Esclerodermia Sistémica/patología , Esclerodermia Sistémica/terapia , Enfermedades Indiferenciadas del Tejido Conectivo/diagnóstico , Enfermedades Indiferenciadas del Tejido Conectivo/patología , Enfermedades Indiferenciadas del Tejido Conectivo/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA